Urogen Pharma Ltd

URGN has resumed a Stage 4 downtrend, driven by the Post-Parabola Collapse pattern and declining EMAs. Medium-term bias is bearish as price makes lower highs and lows and remains below the 9- and 20-day EMAs. Short-term momentum is negative, with price failing at near-term resistance and tracking lower. The momentum-oriented strategy favors continuation participation on rallies into the 9/20 EMA resistance zone (~44.8–45). Initiate Sell Now into that area and avoid chasing further declines.

• ↑Q2 revenue forecast of $62.8M, marking sequential top-line growth
• ↑EPS loss narrowing to $0.28 indicates improving financial momentum
• ↓Sustained $0.28 EPS loss underscores persistent profitability challenges